Cambridge Cancer Genomics develops precision oncology solutions that utilize genomic profiling and data analytics to tailor cancer treatments to individual patients. This approach addresses the inefficiencies in traditional cancer therapies by providing personalized treatment plans based on specific genetic markers and tumor characteristics.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer treatments often follow a one-size-fits-all approach, which can be ineffective due to the unique genetic makeup of each patient's cancer. This can lead to unnecessary side effects and suboptimal outcomes.
Solution
Cambridge Cancer Genomics (CCG) offers precision oncology solutions that leverage genomic profiling and data analytics to personalize cancer treatments. By analyzing the specific genetic markers and tumor characteristics of individual patients, CCG provides tailored treatment plans that address the inefficiencies of traditional cancer therapies. This approach aims to improve treatment effectiveness and minimize adverse effects by targeting the specific vulnerabilities of each patient's cancer. The company's solutions enable clinicians to make more informed decisions, leading to better patient outcomes and a more personalized approach to cancer care.
Target Audience
The primary customers are oncologists and other healthcare professionals who treat cancer patients, as well as hospitals and cancer centers looking to implement precision medicine approaches.
Features
- Genomic profiling to identify specific genetic markers in a patient's cancer
- Data analytics to interpret genomic data and predict treatment response
- Personalized treatment plans based on individual tumor characteristics